Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 101–200 of 895
Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes
Doherty, J. A., Peres, L. C., Wang, C., Way, G. P., Greene, C. S., & Schildkraut, J. M. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0115-y · Cited by 112
“The other histotypes rarely harbor TP53 mutations, and instead have mutations in KRAS (MC), CTNNB1 (EC), PTEN (EC), and PIK3CA (CCC) [5, 22, 37]. Pathology review of cell type is now highly reproducible and is considered the “gold standard” for histotype classification. In some cases, IHC markers can help with classif…”
BackgroundMethodInfluentialDeep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images
Farahani, H., Boschman, J., Farnell, D., Darbandsari, A., Zhang, A. A., Ahmadvand, P., Jones, S. J. M., Huntsman, D. D., Köbel, M., Gilks, C. B., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01146-z · Cited by 113
“These fi ve common histotypes have distinct cellular morphologies and etiologies, as well as molecular, genetic, and clinical attributes 2,3 .”
BackgroundSelf-citationUnmasking the complexities of mucinous ovarian carcinoma
Frumovitz, M., Schmeler, K. M., Malpica, A. L., Sood, A. K., & Gershenson, D. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.010 · Cited by 112
“[22] evaluated 21 proteins with immunohistochemistry in 500 ovarian cancer specimens.”
Type II transmembrane serine proteases in cancer and viral infections
Choi, S.-Y., Bertram, S., Glowacka, I., Park, Y. W., & Pöhlmann, S. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.05.003 · Cited by 112
Borjabad, A., Morgello, S., Chao, W., Kim, S.-Y., Brooks, A. I., Murray, J., Potash, M. J., & Volsky, D. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002213 · Cited by 111
Calculator for ovarian carcinoma subtype prediction
Kalloger, S. E., Köbel, M., Leung, S. C. Y., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. D., & Gilks, C. B. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.215 · Cited by 112
“7 and are best considered to be distinct disease entities”
BackgroundSelf-citationAfamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer
Dieplinger, H., Ankerst, D. P., Burges, A., Lenhard, M., Lingenhel, A., Fineder, L., Buchner, H., & Stieber, P. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0653 · Cited by 111
“The expression of CA125 and of most other established or candidate tumor markers for ovarian cancer differs significantly between histologic subtypes but does not vary across stages within each subtype (33).”
BackgroundOvarian cancer biomarkers for molecular biosensors and translational medicine
Suh, K. S., Park, S. W., Castro, A., Patel, H., Blake, P., Liang, M. N., & Goy, A. H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.87 · Cited by 111
Human ovarian cancer stem cells
Bapat, S. A. (2010) · Reproduction · doi:10.1530/rep-09-0389 · Cited by 111
The role of novel biomarker HE4 in endometrial cancer: a case control prospective study
Angioli, R., Plotti, F., Capriglione, S., Montera, R., Damiani, P., Ricciardi, R., Aloisi, A., Luvero, D., Cafà, E. V., Dugo, N., et al. (2012) · Tumor Biology · doi:10.1007/s13277-012-0583-0 · Cited by 110
Zhang, X., Yao, J., Li, X., Niu, N., Liu, Y., Hajek, R. A., Peng, G., Westin, S. N., Sood, A. K., & Liu, J. (2023) · Science Advances · doi:10.1126/sciadv.adf7195 · Cited by 110
Madore, J., Ren, F., Filali‐Mouhim, A., Sanchez, L. M., Köbel, M., Tonin, P. N., Huntsman, D. D., Provencher, D. M., & Mes‐Masson, A. (2009) · The Journal of Pathology · doi:10.1002/path.2659 · Cited by 111
Self-citationParra‐Herran, C., Lerner‐Ellis, J. P., Xu, B., Khalouei, S., Bassiouny, D., Cesari, M., Ismiil, N. D., & Nofech‐Mozes, S. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.81 · Cited by 109
Hussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 109
Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms
Hellström, I., Heagerty, P. J., Swisher, E. M., Liu, P., Jaffar, J., Agnew, K. J., & Hellström, K. E. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.013 · Cited by 108
“There is a need for non-invasive assays to aid the early detection of ovarian carcinoma, and particularly its most aggressive serous form [1,2].”
BackgroundSerum HE4 as a prognostic marker in endometrial cancer — A population based study
Brennan, D. J., Hackethal, A., Metcalf, A., Coward, J. I. G., Ferguson, K., Oehler, M. K., Quinn, M. A., Janda, M., Leung, Y. C., Freemantle, M., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.10.036 · Cited by 107
“Human epididymis protein 4 (HE4), initially identified as one of four cDNAs highly expressed in the human epididymis [11] is a secreted protein that is overexpressed in patients with serous and endometrioid epithelial ovarian [12,13] and uterine cancers [14–16].”
BackgroundDNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines
Houshdaran, S., Hawley, S., Palmer, C., Campan, M., Olsen, M. N., Ventura, A. P., Knudsen, B. S., Drescher, C. W., Urban, N. D., Brown, P. O., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009359 · Cited by 97
“While this notion is common knowledge among clinicians, and is reflected in studies of tumor gene expression [41] and protein expression [42], regrettably, it is often ignored in molecular diagnostic studies, and all cases of ovarian cancer are still treated similarly in clinic despite their acknowledged differences i…”
BackgroundSelf-citationHistotype classification of ovarian carcinoma: A comparison of approaches
Peres, L. C., Cushing‐Haugen, K. L., Anglesio, M. S., Wicklund, K. G., Bentley, R. C., Berchuck, A., Kelemen, L. E., Nazeran, T. M., Gilks, C. B., Harris, H. R., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.016 · Cited by 107
“Ovarian carcinoma is heterogeneous, consisting of distinct histotypes with unique epidemiologic characteristics, molecular features, clinical presentations, and prognostic outcomes [1,2].”
BackgroundSelf-citationPark, Y., Lee, J.-H., Hong, D. J., Lee, E. Y., & Kim, H.-S. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.04.011 · Cited by 106
HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma
Mahajan, A., Liu, Z., Gellert, L. L., Zou, X., Yang, G., Lee, P., Yang, X. J., & Wei, J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.49 · Cited by 105
“Genome-wide global gene analysis further defines distinct expression profiles of different types of ovarian cancer”
BackgroundLowery, W. J., Schildkraut, J. M., Akushevich, L., Bentley, R., Marks, J. R., Huntsman, D., & Berchuck, A. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318231f140 · Cited by 96
Self-citationHamed, E. O., Ahmed, H., Sedeek, O. B., Mohammed, A. M., Abdalla, A. A., & Abdelghafar, H. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-11 · Cited by 103
“investigated the variation in expression of 21 different markers in accordance with ovarian cancer subtypes, and concluded that most markers differ significantly between histological types [39].”
BackgroundTandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
McBride, D. J., Etemadmoghadam, D., Cooke, S. L., Alsop, K., George, J., Butler, A., Cho, J., Galappaththige, D., Greenman, C., Howarth, K. D., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4042 · Cited by 97
Chen, J., Zhang, X., Cao, R., Lu, X., Zhao, S., Fekete, Á., Huang, Q., Schmitt‐Kopplin, P., Wang, Y., Xu, Z., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200173q · Cited by 101
Cochrane, D. R., Tessier‐Cloutier, B., Lawrence, K. M., Nazeran, T. M., Karnezis, A. N., Salamanca, C. M., Cheng, A. S., McAlpine, J. N., Hoang, L. N., Gilks, C. B., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4934 · Cited by 101
Self-citationPrognostic role of CIP2A expression in serous ovarian cancer
Böckelman, C., Lassus, H., Hemmes, A., Leminen, A., Westermarck, J., Haglund, C., Bützow, R., & Ristimäki, A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.346 · Cited by 100
“Previous studies have suggested distinct molecular pathogenesis and clinical manifestation for different histological types (Kobel et al, 2008), and hence, we decided to limit our study to serous histological type.”
BackgroundPathology of borderline and invasive cancers
Prat, J. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.08.007 · Cited by 99
Cancer molecular markers: A guide to cancer detection and management
Nair, M., Sandhu, S. S., & Sharma, A. K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.002 · Cited by 98
Intake of dietary flavonoids and risk of epithelial ovarian cancer
Cassidy, A., Huang, T., Rice, M. S., Rimm, E. B., & Tworoger, S. S. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.088708 · Cited by 92
Endometrial carcinomas with ambiguous features
Soslow, R. A. (2010) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2010.09.003 · Cited by 96
Tomao, F., Papa, A., Rossi, L., Strudel, M., Vici, P., Lo Russo, G., & Tomao, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-48 · Cited by 92
“cells as well [104-110].”
Endometriosis-associated Ovarian Cancers
ANGLESIO, M. S., & YONG, P. J. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000320 · Cited by 85
Protein Biomarkers of Ovarian Cancer: The Forest and The Trees
Nolen, B. M., & Lokshin, A. E. (2011) · Future Oncology · doi:10.2217/fon.11.135 · Cited by 91
Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers
Mackenzie, R., Talhouk, A., Eshragh, S., Lau, S., Cheung, D., Chow, C., Le, N. D., Cook, L. S., Wilkinson, N., McDermott, J. R., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000476 · Cited by 91
“Generally, the cases of EOC with mixed morphologic features studied herein fall within 1 of 2 main groupings: (1) tumors with uniform molecular features throughout, consistent with their being a single histotype, but displaying morphologic plasticity within distinct regions, and (2) tumors in which the observed hetero…”
BackgroundSelf-citationKim, Y. M., Whang, D. H., Park, J., Kim, S. H., Lee, S., Park, H. A., Ha, M., & Choi, K. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.085 · Cited by 90
“According to a previous study, it has been affirmed that biomarker expression is more strongly associated with the ovarian carcinoma subtype than with the stage, since ovarian carcinoma subtypes are different disease (21).”
BackgroundHüttenhain, R., Choi, M., de la Fuente, L. M., Oehl, K., Chang, C.-Y., Zimmermann, A., Malander, S., Olsson, H. L., Šurinová, S., Clough, T., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001221 · Cited by 90
“The list was further augmented with biomarker candidates, either previously discovered or from ongoing cancer biomarker studies (26-30).”
BackgroundKöbel, M., Kalloger, S. E., Lee, S., Duggan, M. A., Kelemen, L. E., Prentice, L., Kalli, K. R., Fridley, B. L., Visscher, D. W., Keeney, G. L., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0391 · Cited by 90
“Studies in recent years have revealed that ovarian carcinoma is not a single disease entity and that histological type is a reasonable first stratification (1-3).”
Self-citationNon-coding somatic mutations converge on the PAX8 pathway in ovarian cancer
Corona, R. I., Seo, J.-H., Lin, X., Hazelett, D. J., Reddy, J., Fonseca, M. A., Abbasi, F., Lin, Y. G., Mhawech-Fauceglia, P. Y., Shah, S. P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15951-0 · Cited by 90
Self-citationThériault, B. L., Pajovic, S., Bernardini, M. Q., Shaw, P. A., & Gallie, B. L. (2011) · International Journal of Cancer · doi:10.1002/ijc.26189 · Cited by 89
“We present for the first time evidence that expression of a mitotic kinesin is an independent prognostic indicator for progression-free survival in OvCa, providing support for the clinical utility of KIF14 as a marker of outcome in OvCa.”
BackgroundInfluentialKessler, M., Zielecki, J., Thieck, O., Mollenkopf, H., Fotopoulou, C., & Meyer, T. F. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.015 · Cited by 89
Genome-wide significant risk associations for mucinous ovarian carcinoma
Kelemen, L. E., Lawrenson, K., Lee, J. M., Spindler, T. J., Lee, A. W., Pearce, C. L., Pike, M. C., Ramus, S. J., Wu, A. H., Gayther, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3336 · Cited by 89
Predicting master transcription factors from pan-cancer expression data
Reddy, J., Fonseca, M. A., Corona, R. I., Nameki, R. A., Dezem, F. S., Klein, I. A., Chang, H. S. Y., Chaves‐Moreira, D., Afeyan, L. K., Malta, T. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6123 · Cited by 88
HE4 in ovarian cancer: from discovery to clinical application.
Montagnana, M., Danese, E., Giudici, S., Franchi, M. P., Guidi, G. C., Plebani, M., & Lippi, G. (2011) · PubMed · Cited by 87
Quantification of ER/PR expression in ovarian low-grade serous carcinoma
Escobar, J., Klimowicz, A. C., Dean, M. L., Chu, P., Nation, J. G., Nelson, G. S., Ghatage, P., Kalloger, S. E., & Köbel, M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.10.013 · Cited by 87
Self-citationArtificial intelligence in ovarian cancer histopathology: a systematic review
Breen, J., Allen, K., Zucker, K., Adusumilli, P., Scarsbrook, A. F., Hall, G. D., Orsi, N. M., & Ravikumar, N. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00432-6 · Cited by 86
Beyond N-Cadherin, Relevance of Cadherins 5, 6 and 17 in Cancer Progression and Metastasis
Casal, J. I., & Bartolomé, R. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133373 · Cited by 85
“been observed in ovarian carcinoma [90,91], thyroid cancers [92,93], cholangiocarcinoma [94], 277 Figure 1.”
BackgroundElschenbroich, S., Ignatchenko, V., Clarke, B., Kalloger, S. E., Boutros, P. C., Gramolini, A. O., Shaw, P., Jurisica, I., & Kislinger, T. (2011) · Journal of Proteome Research · doi:10.1021/pr1011087 · Cited by 82
Self-citationCheng, J., Klausen, C., & Leung, P. C. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.029 · Cited by 84
“However, increasing evidence indicates that ovarian cancer subtypes are different diseases [38,39].”
Assignment of primary site in high‐grade serous tubal, ovarian and peritoneal carcinoma: a proposal
Singh, N., Gilks, C. B., Wilkinson, N., & McCluggage, W. G. (2014) · Histopathology · doi:10.1111/his.12419 · Cited by 84
Self-citationO'Shannessy, D. J., Somers, E. B., Wang, L.-C., Wang, H., & Hsu, R. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0156-0 · Cited by 83
“0/ ovarian [2–4] and other gynecologic malignancies in order to identify new targets for potential therapy and new modes of diagnosis.”
BackgroundBreen, J., Allen, K., Zucker, K., Godson, L., Orsi, N. M., & Ravikumar, N. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00799-8 · Cited by 81
“It is represented by an array of histological (morphological) subtypes with distinct prognoses and treatment options 2 .”
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer
Muralidhar, G. G., & Barbolina, M. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160816833 · Cited by 81
“Each of the histotypes has been found to be associated with mutations in specific genes and have different clinical manifestations [35].”
BackgroundHarrington, B. S., He, Y., Davies, C. M., Wallace, S. J., Adams, M. N., Beaven, E. A., Roche, D., Kennedy, C. J., Chetty, N., Crandon, A. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.471 · Cited by 80
“Although WT1 staining, which characteristically shows diffuse strong nuclear positivity in 80–90% of HGSCs (Al-Hussaini et al, 2004; Kobel et al, 2008), was only weakly present in the cytoplasm of SKOV3 xenografts, immunohistochemistry for CA125 and cytokeratins 7 and 20 was consistent with HGSC…”
BackgroundResultSelf-citationTworoger, S. S., & Huang, T. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42542-9_9 · Cited by 80
Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective
Montagnana, M., Benati, M., & Danese, E. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.05.13 · Cited by 80
“On the other hand, other studies reported that CA125 expression is more strongly associated with OC subtype than with stage (20).”
BackgroundBondeson, D. P., Paolella, B. R., Asfaw, A., Rothberg, M. V., Skipper, T. A., Langan, C., Mesa, G., Gonzalez, A., Surface, L. E., Ito, K., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00360-7 · Cited by 71
Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type
Gaitskell, K. L., Green, J., Pirie, K. L., REEVES, G. K., & Collaborators, V. B. O. B. O. T. M. W. S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29856 · Cited by 79
Wiegand, K. C., Hennessy, B. T., Leung, S. C. Y., Wang, Y., Ju, Z., Murray, M. M., Kalloger, S. E., Finlayson, S. J., Stemke‐Hale, K., Lu, Y., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-120 · Cited by 79
“Background There are important clinical and molecular differences between histological subtypes of ovarian cancer [1,2].”
Self-citationLau, T., Chung, T. K. H., Cheung, T., Chan, L. K., Cheung, L. W., Yim, S. F., Siu, N. S. S., Lo, K. W., Yu, M. M. Y., Kulbe, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4258 · Cited by 78
“Pathological and genomic findings indicate that these malignancies share few molecular similarities and some are derived from non-ovarian tissues [2,3].”
BackgroundmiRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Ravaggi, A., Martini, P. G. V., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0360 · Cited by 78
Ali, R. H., Seidman, J. D., Luk, M., Kalloger, S. E., & Gilks, C. B. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824d7445 · Cited by 77
“A database derived from studies of a populationbased series of 500 cases of ovarian carcinoma (9) was used to search for tumors with an immunoprofile similar to that of BTs.”
MethodSelf-citationMolecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
Gilks, C. B. (2010) · Journal of Oncology · doi:10.1155/2010/740968 · Cited by 64
“Clear cell carcinomas show relatively low-mitotic rates [5, 23], and it is therefore not surprising that responses to agents targeting dividing cells are less successful than those in high-grade serous carcinoma.”
BackgroundSelf-citationMullany, L. K., Fan, H.-Y., Liu, Z., White, L. D., Marshall, A. N., Gunaratne, P. H., Anderson, M. L., Creighton, C. J., Xin, L., Deavers, M. T., et al. (2011) · Oncogene · doi:10.1038/onc.2011.70 · Cited by 76
“Genes encoding matrix components were also observed (Schwartz et al., 2002; Malpica et al., 2004; Santin et al., 2004; Cheng et al., 2005; Kobel et al., 2008; Konstantinopoulos et al., 2008; Cho and Shih, 2009; Gorringe and Campbell, 2009; Despierre et al., 2010; Gava et al., 2008) (Supplementary Table S3).”
BackgroundThe Role of Nuclear β-Catenin Accumulation in the Twist2-Induced Ovarian Cancer EMT
Mao, Y., Xu, J., Li, Z., Zhang, N., Yin, H., & Liu, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078200 · Cited by 76
“The vast majority of women are diagnosed with disseminated intraperitoneal carcinomatosis [1,2].”
BackgroundPark, Y., Kim, Y., Lee, E. Y., Lee, J., & Kim, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.26129 · Cited by 76
Jo, A., Green, A., Medina, J. E., Iyer, S., Öhman, A., McCarthy, E. T., Reinhardt, F., Gerton, T. J., Demehin, D., Mishra, R. K., et al. (2023) · Advanced Science · doi:10.1002/advs.202301930 · Cited by 76
The origin of ovarian cancers - hypotheses and controversies
Auersperg, N. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s401 · Cited by 75
“Small amounts of mesothelin are secreted by fimbrial epithelium (19) Mesothelin is a specific differentiation marker for mesothelia, and a major marker in HGSOCs (1) Mesothelin in fimbriae (19) reflects the mesothelial origin of the Mullerian ducts and thus of the oviductal epithelium”
BackgroundInfluentialMoore, R. G., Miller, C., Brown, A., Robison, K. M., Steinhoff, M. M., & Lambert-Messerlian, G. M. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182229ad8 · Cited by 75
“Human epididymis protein 4 (HE4), a novel tumor marker, circulates in the bloodstream and is overexpressed in patients with serous and endometrioid epithelial ovarian carcinomas and uterine cancers.(17,18) Human epididymis protein 4 (WFDC2) is made up of 2 whey acidic protein domains and a 4-disulfide core and is part…”
BackgroundProteomics of ovarian cancer: functional insights and clinical applications
Elzek, M., & Rodland, K. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9547-8 · Cited by 75
“Recent studies show less significant changes across grade or stage compared with histologic type [3, 34].”
BackgroundDevelopment of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer
An, Y., Bi, F., You, Y., Liu, X., & Yang, Q. F. (2018) · Journal of Cancer · doi:10.7150/jca.25587 · Cited by 74
“As the most lethal gynecological cancer world-wide, the incidence of ovarian cancer has increased [1, 2].”
BackgroundThe Oviduct and Ovarian Cancer: Causality, Clinical Implications, and “Targeted Prevention”
Crum, C. P., McKeon, F., & Xian, W. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31824b1725 · Cited by 74
Ordóǹez, N. G. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.200 · Cited by 74
Gaudin, F., Nasreddine, S., Donnadieu, A.-C., Émilie, D., Combadière, C., Prevot, S., Machelon, V., & Balabanian, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021546 · Cited by 73
“Each subtype is characterized by a specific mRNA profile, genetic risk factors and molecular features [34] [40–41], suggesting that ovarian carcinoma is a heterogeneous disease [42].”
BackgroundBiomarker Discovery for Heterogeneous Diseases
Wallstrom, G. L., Anderson, K. S., & LaBaer, J. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1236 · Cited by 73
Nunna, S., Reinhardt, R., Ragozin, S., & Jeltsch, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087703 · Cited by 73
“ovarian cells [10–14].”
Krämer, P., Talhouk, A., Brett, M. A., Chiu, D. S., Cairns, E. S., Scheunhage, D. A., Hammond, R. F. L., Farnell, D., Nazeran, T. M., Grube, M. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1268 · Cited by 73
“Today, the scientific community widely agrees that ovarian carcinoma is a heterogeneous disease and that different histological types are best considered as different disease entities [1].”
BackgroundSelf-citationAndersen, J. D., Boylan, K. L. M., Xue, F. S., Anderson, L., Witthuhn, B. A., Markowski, T. W., Higgins, L., & Skubitz, A. P. N. (2010) · Electrophoresis · doi:10.1002/elps.200900441 · Cited by 72
Defining a comprehensive verotype using electronic health records for personalized medicine
Boland, M. R., Hripcsak, G., Shen, Y., Chung, W. K., & Weng, C. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-001932 · Cited by 67
Singh, N., Gilks, C. B., Wilkinson, N., & McCluggage, W. G. (2015) · Pathology · doi:10.1097/pat.0000000000000291 · Cited by 72
Self-citationAltman, A. D., Nelson, G. S., Ghatage, P., McIntyre, J. B., Capper, D., Chu, P., Nation, J. G., Karnezis, A. N., Han, G., Kalloger, S. E., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.55 · Cited by 71
Self-citationOvarian cancer molecular pathology
Longuespée, R., Boyon, C., Desmons, A., Vinatier, D., Leblanc, É., Farré, I., Wisztorski, M., Ly, K., D’Anjou, F., Day, R. W., et al. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9383-7 · Cited by 71
“PDEF (prostate-derived Ets factor) [116,205]”
Montagnana, M., Danese, E., Giudici, S., Franchi, M. P., Guidi, G. C., Plebani, M., & Lippi, G. (2011) · Advances in clinical chemistry · doi:10.1016/b978-0-12-387042-1.00001-0 · Cited by 71
“[16] observed that CA125 expression was more strongly associated with ovarian cancer subtype versus stage.”
BackgroundType II Transmembrane Serine Protease (TTSP) deregulation in cancer
Siobhan, L. W. (2010) · Frontiers in bioscience · doi:10.2741/3704 · Cited by 70
“Matriptase has been found to be up-regulated in many epithelial tumors, including breast, colon, kidney, liver, lung, mesothelioma, ovarian and prostate cancers, and is a potential diagnostic and prognostic biomarker (2, 35, 39-42).”
BackgroundCadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway
Sancisi, V., Gandolfi, G., Ragazzi, M., Nicoli, D., Tamagnini, I., Piana, S., & Ciarrocchi, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075489 · Cited by 69
“This is in line with what has been reported in ovarian cancer and renal carcinomas, where an overexpression of CDH6 is observed in tumor cells as compared with the normal counterpart [14,15].”
BackgroundResultKeita, M., Wang, Z.-Q., Pelletier, J.-F., Bachvarova, M., Plante, M., Gregoire, J., Renaud, M., Mes‐Masson, A., Paquet, É. R., & Bachvarov, D. R. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.036 · Cited by 69
“Recent studies were strongly indicative for ovarian carcinoma subtypes being different diseases that should be investigated separately in order to define reliable risk and therapy predictors [10].”
BackgroundKöbel, M., Luo, L., Grevers, X., Lee, S., Brooks-Wilson, A. R., Gilks, C. B., Le, N. D., & Cook, L. S. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000530 · Cited by 69
“Eligible cases were: (1) diagnosed with incident ovarian tumors; (2) residents of the provinces; (3) age 20 to 79 yr (40–79 in AB); (4) English-speaking; (5) alive at study contact; and (6) able to complete an interview/self-administered questionnaire.”
Self-citationThe emerging epidemic of estrogen‐related cancers in young women in a developing Asian country
Lin, C., Chen, Y., Chiang, C., Lu, Y., Kuo, K., Huang, C., Cheng, W., Lai, M., You, S., & Cheng, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26249 · Cited by 69
Cheng, C., Licence, D., Cook, E., Luo, F., Arends, M. J., Smith, S. K., Print, C. G., & Charnock‐Jones, D. S. (2011) · The Journal of Pathology · doi:10.1002/path.2852 · Cited by 63
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma
Lassus, H. J., Staff, S. M., Leminen, A., Isola, J. J., & Bützow, R. C. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.09.003 · Cited by 68
“However, it has been shown that the histological types have distinct molecular pathogenesis and clinical behavior [15–19].”
BackgroundBignotti, E., Calza, S., Tassi, R. A., Zanotti, L., Bandiera, E., Sartori, E., Odicino, F. E., Ravaggi, A., Todeschini, P., & Romani, C. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12927 · Cited by 68
“Epithelial ovarian cancer is the fifth most common type of cancer in women and the leading cause of mortality for gynaecological neoplasms, with high-grade serous carcinoma (HGS-OvCa) being the most frequent and aggressive histological type [1].”
BackgroundTassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0536-y · Cited by 67
“These sub-types are very different entities carrying distinct gen-etic risk factors, molecular signatures, prognoses and responses to treatment [3, 4].”
Ovarian carcinoma diagnosis: the clinical impact of 15 years of change
Kommoss, S., Gilks, C. B., du Bois, A., & Kommoss, F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.273 · Cited by 67
“…led to the proposal that histotypes of ovarian carcinoma are best considered to be separate disease entities differing with respect to precursor lesions, molecular events during oncogenesis, pattern of spread, response to chemotherapy, and outcome (Kobel et al, 2008; McCluggage, 2011; Prat, 2012a).”
BackgroundSelf-citationMcAlpine, J. N., Hallani, S. E., Lam, S. F., Kalloger, S. E., Luk, M. T., Huntsman, D. D., MacAulay, C. E., Gilks, C. B., Miller, D. M., & Lane, P. M. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.12.333 · Cited by 67
Self-citationToyama, A., Suzuki, A., Shimada, T., Aoki, C., Aoki, Y., Umino, Y., Nakamura, Y., Aoki, D., & Sato, T. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02224.x · Cited by 69
Davidson, B., Stavnes, H. T., Holth, A., Xu, C., Yang, Y., Shih, I., & Wang, T. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01023.x · Cited by 67
Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer
Ryu, J., & Thomas, S. N. (2021) · Molecules · doi:10.3390/molecules26092674 · Cited by 66
“EOC, which is the most dangerous of all types of ovarian cancers, develops from the cells covering the outer surface of the ovaries and is classified into five subtypes based on tumor cell histology: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous ovarian cancers [15,16].”
BackgroundHistotype predicts the curative potential of radiotherapy: the example of ovarian cancers
Swenerton, K. D., Santos, J. L., Gilks, C. B., Köbel, M., Hoskins, P. J., Wong, F., & Le, N. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq383 · Cited by 66
“This allowed application of current classification criteria [1, 2] and assignment into the following histotypes: serous (S), clear cell (C), endometrioid (E), mucinous (M), and other (O), the latter a heterogeneous group including transitional cell, squamous cell, and unclassifiable carcinomas.”
BackgroundSelf-citationAttributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary
Samardzija, C., Quinn, M. A., Findlay, J. K., & Ahmed, N. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-37 · Cited by 66
“The differences in the expression of Oct4 between serous and mucinous EOC may be due to the differences in the genetic makeup of serous and mucinous subtypes of ovarian tumors [71].”
BackgroundSernbo, S., Gustavsson, E., Brennan, D. J., Gallagher, W. M., Rexhepaj, E., Rydnert, F., Jirström, K., Borrebaeck, C. A. K., & Ek, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-405 · Cited by 65
“It has been emphasized that each EOC subtype needs to be considered separately in order to identify clinically relevant biomarkers [5].”
In vitro three-dimensional modeling of fallopian tube secretory epithelial cells
Lawrenson, K., Notaridou, M., Lee, N., Benjamin, E. O., Jacobs, I. J., Jones, C., & Gayther, S. A. (2013) · BMC Cell Biology · doi:10.1186/1471-2121-14-43 · Cited by 64
“Almost all cells in FTSEC cultures expressed the lineagespecific marker PAX8 in the nucleus (Figure 1a), indicating that the cell culture protocol enriched for fallopian tube secretory epithelial cells (FTSECs) [1,13].”
BackgroundInfluential
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.